Clinical Trials Browser

Phase 2 × Carcinoma, Non-Small-Cell Lung × brigatinib × Clear all

NCT04223596 2026-02-04

CUBIK

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05200481 2025-11-17

MP-ALK

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT06522360 2025-04-24

Brigatinib Plus Chemotherapy or Local Consolidation Therapy in ALK Positive Advanced Non-small Cell Lung Cancer (BrightStar-2)

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT04322890 2024-10-22

PIKACHU

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT05718297 2024-10-08

BOUNCE

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT05014464 2024-09-20

ATPase

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT04591431 2023-10-03

ROME

Phase 2 Unknown

BreastGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms

NCT04074993 2023-09-28

Brigatinib in ALK-positive NSCLC Identified Via Blood-based Assays

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT05361564 2022-05-04

A Window of Opportunity Study for Investigating Drug Tolerant Persister (DTP) to Preoperative Brigatinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harboring ALK Fusions.

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT02094573 2021-03-15

A Study to Evaluate the Efficacy of Brigatinib (AP26113) in Participants With Anaplastic Lymphoma Kinase (ALK)-Positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib

Phase 2 Completed

222 enrolled 23 charts

Carcinoma, Non-Small-Cell Lung